SlowBull
The Business Brief WEDNESDAY, 9 SEPTEMBER 2026
← All stories
Markets

A new immuno-oncology play raises $225M for a next-generation drug

1 source ·1 article ·2h ago

Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·2h ago

A new immuno-oncology play raises $225M for a next-generation drug

Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.